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Introduction
The SEER program (Surveillance, Epidemiology, and End 
Results) Stat Fact Sheets had reported that 45 780 new cases 
of oral cavity and pharynx cancer have been identified and 
it was estimated that 8650 people will die of this disease.1 
The risk factors of oral cancer include nutritional deficien-
cies, environment, and lifestyle such as consumption of 
alcoholic products, tobacco, and betel quid chewing.2,3 As 
stated by the World Health Organization (WHO), the inci-
dence of oral cancer varies markedly worldwide but glob-
ally it is believed to be the 10th most common malignant 
tumor. Approximately 30% to 35% of cancer deaths in the 
United States were linked to diet.4,5
A clear majority (>80%) of patients prefer oral chemo-
therapy, but only provided this is not at the expense of 
efficacy.6,7 The preference for oral chemotherapy stems 
largely from the greater convenience of treatment at home 
(cited by 57% of patients) and avoidance of venipunctures 
(55%). There are additional concerns with protracted infu-
sional regimens where many patients experience problems 
with indwelling venous catheters. A third of patients also 
cited the greater sense of “control” over their treatment that 
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Abstract
Cancers involving the oral cavity, head, and neck regions are often treated with cisplatin. In cancer therapy, the main 
target is to eliminate unwanted cancerous cells. However, reports on the nonselective nature of this drug have raised few 
concerns. Incorrect nutritional habits and lifestyle practices have been directly linked to cancer incidence. Nutrients with 
antioxidant activity inhibit cancer cells development, destroying them through oxidative stress and apoptosis. α-tocopherol, 
the potent antioxidant form of vitamin E is a known scavenger of free radicals. In vitro study exhibited effective antitumor 
activity of α-tocopherol on ORL-48 at 2.5 ± 0.42 µg/mL. Cisplatin exhibited stronger activity at 1.0 ± 0.15 µg/mL, but unlike 
α-tocopherol it exhibited cytotoxicity on normal human epidermal keratinocytes at very low concentration (<0.1 µg/mL). 
Despite the lower potency of α-tocopherol, signs of apoptosis such as the shrinkage of cells and appearance of apoptotic 
bodies were observed much earlier than cisplatin in time lapse microscopy. No apoptotic vesicles were formed with 
cisplatin, instead an increased population of cells in the holoclone form which may suggest different induction mechanisms 
between both agents. High accumulation of cells in the G0/G1 phase were observed through TUNEL and annexin V-biotin 
assays, while the exhibition of ultrastructural changes of the cellular structures verified the apoptotic mode of cell death by 
both agents. Both cisplatin and α-tocopherol displayed cell cycle arrest at the Sub G0 phase. α-tocopherol thus, showed 
potential as an antitumour agent for the treatment of oral cancer and merits further research.
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they would gain from oral chemotherapy.7 Quality of life is 
especially important in the palliative setting and oral treat-
ment can reduce disruption of home life for both patient and 
their family.8,9
Despite encouraging findings on potentially effective 
agents and drugs on cancer cells, chemotherapeutic treat-
ments are usually not completely selective for carcinogenic 
cells. Alongside induction of apoptosis on tumor cells, anti-
cancer agents often also induce apoptosis in normal tissues. 
Searle et al10 had earlier realized that apoptotic cell death is 
induced in a subset of normal tissues, which lead to his sug-
gestion that the process may contribute to toxicity associ-
ated with chemotherapy. As a consequence of these 
cytotoxic effects on normal cells, the quality of life of 
patients with cancer may be lowered.11 In other words, stud-
ies suggested that drug-induced apoptosis also causes the 
loss of normal cell and thus, can contribute to the side 
effects of cancer therapy.12
Vitamin E is the term for a group of tocopherols (α, β, γ, 
δ) and tocotrienols (α, β, γ, δ) of which α-tocopherol has the 
highest biological activity. The 8 members of the vitamin E 
family are potent antioxidants since they all possess a free 
phenol hydroxyl group in their functional moiety. Vitamin 
E is relatively nontoxic and well tolerated by humans.11 The 
impact of α-tocopherol in the prevention of chronic diseases 
believed to be associated with oxidative stress has often 
been studied, and beneficial effects were demonstrated.13 It 
has been reported to induce apoptosis in erythroid leuke-
mia, prostate cancer cells, and breast cancer cells.14 Many 
studies in the literature suggested vitamin E a suitable can-
didate for the adjuvant treatment of cancer since it is an 
important micronutrient essential for preserving balance 
between antioxidant and pro-oxidant reactions in tissues.11 
Naturally, α-tocopherol is predominantly found in peanuts, 
almonds, and sunflower seeds.15
Research involving natural products in designing effec-
tive chemotherapy for oral cancer is well recognized in the 
discovery of modern drugs. More than 50% anticancer 
drugs are from compounds and derivatives of natural 
products.16 The essential oil from Levisticum officinale, for 
example, was reported to be effective in inducing growth 
inhibitory activities on human head and neck squamous car-
cinoma cells,17 while honokiol from Magnolia sp. exhibited 
antitumor activities on oral squamous carcinoma cells 
(OSCC).18 Continuous search for new active compounds 
with anticancer activities is necessary to increase availabil-
ity of agents/compounds with less toxicity but with poten-
tial of producing more effective results.
In an earlier report, Sakagami et al19 attributed the con-
sistent increase of OSCC to the decline in apoptotic poten-
tial and immunity observed in cancerous cells, accompanied 
by the loss of their ability to differentiate.20 Elimination of 
unwanted cells is a programmed activity during which 
apoptosis destroys the unnecessary or harmful cells and 
tissues to apoptotic bodies that are then removed and 
degraded by phagocytosis.21 Outcome of several molecular 
studies suggested that OSCC may result from the imbalance 
of the regulation between cell survival and apoptosis.19 In 
other words, for tissue homeostasis, alongside gene-directed 
program that controls proliferation and differentiation of 
involved cells, the balance can also be regulated by factors 
that influence cell survival.12
Methods
Preparation of Cell Lines
Human OSCC cell line, ORL-48 and human epidermal 
keratinocytes (HEK) were used in the study. ORL-48 
obtained from the Cancer Research Institute and Foundation, 
Subang Jaya Medical Centre (CARIF, Malaysia) was devel-
oped from a female patient with gum tumor. The cell line 
was cultured in DMEM (Delbecco’s modified Eagle 
medium) F-12 medium (Gibco, Gaithersburg, MD, USA) 
supplemented with 10% fetal bovine serum, 2 mL of peni-
cillin-streptomycin and 1 mL of amphotericin B. The HEK 
cell line (CellnTEC, Bern, Switzerland) and cultured in Cnt. 
Prime media (CellnTEC, Bern, Switzerland). Both cell 
lines were incubated at 37°C in a humidified atmosphere 
containing 5% CO
2
 (Thermo Forma, Gaithersburg, MD, 
USA). Keratinocytes represented the normal oral mucosa 
cells in the study and was included to check for the toxicity 
of agents on normal cells.
Preparation of Test Compounds
Cisplatin or commercially known as cis-diammineplatinum 
(III) dichloride (Sigma-Aldrich, Selangor, Malaysia) was 
diluted in 1% dimethyl sulfoxide (DMSO) and later pre-
pared to the desired concentrations for used in experiments. 
α-Tocopherol (Sigma-Aldrich, Selangor, Malaysia) was 
diluted in 100% DMSO as stock solution and further diluted 
to the desired concentrations for used in the experiments 
(DMSO 1%). The DMEM F-12 was used for the dilution to 
the desired concentration.
Assessment of Cytotoxicity
The antiproliferative activity of α-tocopherol and cisplatin 
on ORL-48 and HEK cells were assessed based on a colori-
metric assay using neutral red dye.22 Briefly the ORL-48 
and keratinocytes cells were seeded at 3 × 104 cells/mL in 
96-well plates (Sigma-Aldrich, Selangor, Malaysia). One 
hundred micrograms per milliliter stock of α-tocopherol 
and 2000 µg/mL of cisplatin were diluted to varying con-
centrations of 0.1, 1.0, 2.5, 5.0, 7.5, and 10.0 µg/mL in sepa-
rate wells using DMEM F-12 containing 10% foetal bovine 
serum, 1% penicillin-streptomycin, and amphotericin B. 
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The cultures were incubated in a humidified incubator over 
a period of 72 hours at 37°C and 5% CO
2
. Wells containing 
cells in the absence of the agents represented the negative 
control for the test. Following incubation, the culture 
medium was discarded and replaced with 100 µL neutral 
red (1% v/v). The culture plates were further incubated for 
2 hours after which the cells were washed with 1 mL of 
solution containing 1% sodium dodecyl sulfate. The culture 
plates were placed on a rocker (Sigma-Aldrich, Selangor, 
Malaysia) for 30 minutes and the density of the detached 
viable cells that absorbed the red dye was assessed based on 
the optical absorbance read using an ELISA (enzyme-linked 
immunosorbent assay) microplate reader (BioTek, 
Winooski, VT, USA) at a wavelength of 540 nm. The con-
centration of compounds causing 50% of cell death known 
as the inhibition concentration (IC
50
) was determined by a 
graph of percentage of cell death versus concentrations of 
the compounds. The experiment was repeated three times in 
triplicate (n = 9). Similar procedure was carried out on HEK 
for toxicity evalution purposes. The percentage of inhibi-
tion at every concentration was calculated using the formula 
stated below, where OD denotes optical density.
Percentage of Inhibition
OD control  OD sample
OD contro
=
( )−
l
×100%
DNA Fragmentation Analysis
Gel electrophoresis was used to determine the induction of 
apoptosis by observing the band pattern of DNA fragments 
from ORL-48 compound-treated cells.22,23 The Suicide-
Track DNA Ladder Isolation kit (Merck Millipore, Norcross, 
GA, USA) was used for the determination whereby a non-
isotopic method was used for the detection of DNA ladder-
ing in monolayer ORL-48 cells.
DNA Collection. Cells cultured in 6-well titer plates for 48 
hours were detached by the addition of accutase (PAA, Pas-
ching, Austria). Following centrifugation at 4000 rpm, the 
cell pellet was resuspended to a concentration of 5 × 105 to 
1 × 106 cells/mL using a Septer 2.0 cell counter (Merck Mil-
lipore, Norcross, GA, USA). Prior to electrophoresis, the 
cells were centrifuged and resuspended in 55 µL of solution 
#1 (kit component no. JA1825) followed by the addition of 
20 µL of solution #2 (kit component no. JA1826). Follow-
ing an hour’s incubation at 37°C, 25 µL of solution #3 (kit 
component no. JA1827) was added, gently mixed, and rein-
cubated overnight at 50°C. Two microliters of Pellet Paint 
Co-Precipitant (kit component no. JA1836), 60 µL of 3 M 
sodium acetate, and 662 µL of 2-propanol were then added. 
Following gentle mixing, the microvial was left to stand at 
room temperature for 2 minutes or until a pink pellet was 
clearly visible at its bottom. The microvial was centrifuged 
at 15 000 to 16 000 × g for 5 minutes, and the cell pellet was 
rinsed twice with 500 µL of 70% ethanol followed by 500 
µL of 100% ethanol. Following centrifugation, the final cell 
pellet was collected, air dried to remove excess ethanol, and 
resuspended in 50 µL of resuspension buffer.
Gel Preparation. Agarose gel (0.75%) of 0.75 cm thick was 
prepared in TBE (Tris/borate/EDTA) with the addition of 
0.5 mg/mL of ethidium bromide. The agarose mixture was 
poured into an electrophoresis chamber and a gel comb was 
inserted to create wells for the test compounds. Once solidi-
fied, the gel was transferred into a gel buffer tank. Five 
microliters of DNA ladder cells were seeded at concentra-
tion of 3 × 105 cells/2 mL cell culture media into 6-well 
plates. After 24 hours of incubation in a CO
2
 incubator at 
37°C, the cells were treated with the test compounds at 
determined concentrations (0, 2.5, 5.0, 7.5, 10.0 µg/mL). 
The compound-treated cells were further incubated for 72 
hours, after which the cells were washed using 1 mL of 
phosphate buffered saline (PBS) and detached from each 
well by 1 mL of accutase. The cells suspension was then 
centrifuged at 1000 × g for 10 minutes. The DNA in the cell 
pellet was extracted with Suicide TrackTM DNA Isolation 
Kit (Merck Millipore, Norcross, GA, USA), as described by 
the manufacturer. Six microliters of DNA were electropho-
resed on 0.75 % agarose gel containing 5 µg/mL ethidium 
bromide. After electrophoresis, DNA fragments were ana-
lyzed with ultraviolet-illuminated camera. Samples in gel 
loading buffer were carefully loaded into the wells, and 5 
µL of 100 bp laboratory DNA ladder was used as a marker. 
The electrophoresis was run at a constant ∼50 V until the 
dye front has reached 1 to 2 cm from the bottom of the gel. 
The gel was then examined through ultraviolet illumination 
for the detection of DNA products of the compound-treated 
cancer cells.
Assessment of Morphological Activity
Changes to the morphology of ORL-48 cells in response to 
treatment by cisplatin and α-tocopherol were monitored, 
periodically captured and analyzed.23 Briefly, time-lapse 
microscopy analysis was conducted in a setup encompass-
ing a direct heat CO
2
 incubator (Thermo Forma, 
Gaithersburg, MD, USA) and a live resolution digital 
microscope (in incubator) connected to a LCD touch screen 
(Juli Br-Live cell movie analyzer, NanoEn Tek, Pleasanton, 
CA, USA). In the analysis, suspension of cells at a concen-
tration of 3 × 106 cells/mL was dispensed into 6-well titer 
plates prior to the addition of 200 µL of the respective com-
pounds at concentrations of 2.5 µg/mL. The proliferation of 
cells under the influence of the respective compounds was 
closely monitored at specific incubation period of 0, 3, 6, 
24, 48, and 72 hours following the addition of the com-
pounds. Responses of the proliferating cells on exposure to 
the compounds were viewed and captured under Juli 
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Br-Live cell movie analyzer. Images of cells captured at 0 
hours showed distribution of cells prior to treatment. The 
untreated cells represented the control for the experiment. 
The plate was then incubated in a CO
2
 incubator.
Ultrastructural Analysis
Analysis on the effect of α-tocopherol and cisplatin on the 
ultrastructure of intracellular organelles of ORL-48 cells 
was assessed using a transmission electron microscope 
(TEM). Examination of ultrastructural characteristics and 
changes to its morphology induced by α-tocopherol and cis-
platin was focused on monolayer of the respective cells 
treated with 2.5 µg/mL of the respective compound. 
Following the addition of compounds, the monolayers were 
retrieved from the incubator at 3 hours. The extract-treated 
monolayers were then processed for TEM examination. The 
treated monolayer of cells was fixed by adding 4.0% glutar-
aldehyde in phosphate buffer in a dropwise manner over-
night. The fixative was discarded and the monolayers were 
washed 2 to 3 times using cacodylate buffer. The monolay-
ers were postfixed in osmium tetroxide for 2 hours at 4°C. 
The fixed cells were then washed with cacodylate buffer 
and double distilled water. They were then dehydrated 
through a graded series of ethanol (concentration range of 
35%, 50%, 70%, 95%) and propylene oxide. The sets of 
fixed cell monolayers were then infiltrated with epoxy 
resin, embedded by inverting the cover slips over resin-
filled flat embedding molds. The resins were allowed to 
polymerize overnight at 70°C. After polymerization, the 
cover slips were removed from the resin blocks by brief 
immersion in liquid nitrogen. The resin blocks that con-
tained the cell monolayers, were transversely sectioned to 
approximately 1.0 µm thickness with regard to their culture 
substratum. The sections were stained with lead citrate and 
uranyl acetate. Once the sections were ready, the ultrastruc-
ture of the cells were examined under the TEM. The exami-
nation was mainly focused on the ultrastructural changes 
that occurred in the first 3 hours of treatment.
Immunohistochemical (IHC) Staining Using Flow 
Cytometry: TUNEL Assay
The FragEL DNA Fragmentation Detection Kit (Merck 
Millipore, Norcross, GA, USA) was used for the determina-
tion of terminal deoxynucleotidyltransferase (TdT)–
mediated dUTP nick end labelling (TUNEL) technique. It 
quantitates and detects the presence of apoptotic cells. 
ORL-48 cells were seeded at concentration of 1.0 × 106 
cells/mL into 6-well plates. The cells were treated and then 
placed in a CO
2
 incubator. After the incubation period, the 
cells were pelleted down by centrifugation at 4°C, at a 
speed of 1000 rpm for 5 minutes. The media was removed 
and the cells were resuspended in 4% formaldehyde/PBS to 
a cell density of 1.0 × 106 cells. The suspension was left to 
stand at room temperature for 10 minutes before it was 
again pelleted down by centrifugation. It was suggested by 
the manufacturer that once fixed the cells can be stored at 
4°C for 2 to 6 months. The pelleted cells were collected and 
resuspended in 80% ethanol to fix the cells. One milliliter of 
the fixed cells was then transferred into a fresh microcentri-
fuge tube and centrifuged at 1000 rpm for 5 minutes at room 
temperature. The ethanol was then removed and the cells 
were collected and resuspended in 200 µL of Tris buffered 
saline (TBS) before it was left standing at room temperature 
for 10 minutes. Following that the cells were again pelleted 
down, the TBS removed, and the cells were resuspended in 
100 µL of 20 µg/mL proteinase K. After 5 minutes, the cells 
were pelleted down, resuspended in 100 µL of TdT equili-
bration buffer, and incubated at room temperature for 10 to 
30 minutes. The cells were then collected and 60 µL of TdT 
labeling reaction mixture was added. Following gentle mix-
ing and incubation at 37°C for 1 to 1.5 hours in the dark, the 
reaction mixture was removed by centrifugation and the 
cell pellet was resuspended in 200 µL of TBS. The cells 
were once again washed before a volume of 0.5 mL of TBS 
was added. The cells labeled with Fluorescein-FragEL were 
analyzed using a flow cytometry system FACscanto II (BD 
Biosciences, San Jose, CA, USA) with emission wave-
length at 517 nm.
FITC Annexin V-Biotin Apoptosis Assay
FITC (fluorescein isothiocyanate) Annexin V staining pre-
cedes the loss of membrane integrity that accompanies the 
latest stages of cell death resulting from either apoptotic or 
necrotic processes. FITC Annexin V was used to quantita-
tively determine the percentage of cells within a population 
that are actively undergoing apoptosis. Cisplatin/α-
tocopherol was added to 1 × 106 of ORL-48 cells. Following 
incubation, the treated ORL cells were washed with PBS 
and detached by accutase. Following centrifugation, the cell 
pellet was resuspended in 1X Binding Buffer at a concen-
tration of 1 × 106 cells/mL. One hundred microliters of the 
solution were transferred (1 × 105 cells) to a 5 mL culture 
tube. Five microlitres of FITC Annexin V and 5 µL of prop-
idium iodide (PI) were added. The cells were gently vor-
texed and incubated for 15 minutes at room temperature 
(25°C) in the dark. Finally, 400 µL of 1X Binding Buffer 
was added to each tube. Within 1 hour, analysis by flow 
cytometry (FACscanto II system) was performed.
Cell Cycle Analysis
ORL-48 cells were seeded into 6-well culture plates at 3 × 
104 cells/mL and incubated overnight in 5% CO
2
 humidi-
fied incubator at 37°C. Cells were treated with α-tocopherol 
and cisplatin and further incubated. Accutase was added to 
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detach the treated cells, which were then resuspended in 
PBS and transferred to polypropylene tubes. Cells were har-
vested by centrifugation at 4000 rpm (10 minutes). One 
hundred milliliters of lysis reagent were added to each tube. 
Following a 5-minute incubation at room temperature, the 
cells were stained with 300 mL PI using the Cycle TEST 
TM PLUS DNA Reagent Kit and incubated for 15 minutes 
at 37°C. Cell cycle was read using the Cell Quest software 
within 3 hours. Results were analyzed using the flow 
cytometry system FACscanto.
Statistical Analysis
Results were computed and expressed as mean ± standard 
deviation (SD) from 3 determinations performed in tripli-
cate (n = 9).
Results
Cytotoxicity Activity
Both α-tocopherol and cisplatin exhibited antiproliferative 
activity on ORL-48 cells. The inhibitory concentrations (IC
50
) 
were determined at 2.5 ± 0.4 and 1.0 ± 0.2 µg/mL, respec-
tively for α-tocopherol and cisplatin. The IC
50
 of α-tocopherol 
and cisplatin on keratinocytes were 4.08 ± 0.05 and < 0.1 µg/
mL, respectively (Table 1). This suggested the cytotoxic effect 
of cisplatin on normal human epidermal keratinocytes.
Morphological Responses of ORL-48 to α-
Tocopherol and Cisplatin
At 2.5 µg/mL, α-tocopherol incurred significant changes to 
the morphology of ORL-48 cells with shrinkage of cells 
observed at 3 hours following treatment, which then showed 
the appearance of apoptotic bodies at 24 hours (Figure 1B). 
Gradual reduction in cell population was also observed over 
treatment period from 3 to 72 hours of incubation. 
Comparatively, no change in the morphology of cisplatin-
treated ORL-48 was observed in the first 6 hours of treat-
ment. At 24 hours, the morphology of cells remained 
unchanged but the sizes were observed much smaller. In 
contrast to α-tocopherol, no apoptotic bodies were formed 
with cisplatin (Figure 1A). Instead, a gradual increase in cell 
population was noticed from the 24-hour time point onward.
Ultrastructural Analysis
TEM revealed the ultrastructure of the untreated ORL-48 
cells (Figure 2A) were generally round. The nucleus is 
round and contained 1 prominent nucleolus. No signs of 
chromatin condensation and the cells were cells actively 
undergoing division (Figure 2B). By contrast, for ORL-48 
treated with 2.5 µg/mL of cisplatin and α-tocopherol, none 
of the cells were found undergoing division. Instead of the 
enlargement of the nucleus size, vacuole formation, signs of 
chromatin condensation, and blebbing of membrane plasm 
was observed for both treatments. The nucleolus gets 
smaller with the treatment of 2.5 µg/mL cisplatin.
DNA Fragmentation Analysis
Agarose gel electrophoresis performed on ORL-48 treated 
with 2.5, 5.0, 7.5, and 10.0 µg/mL cisplatin showed the 
presence of DNA fragments in clear bands that appeared in 
ladder pattern. The column of bands with the highest den-
sity was obtained following treatment of ORL-48 with 7.5 
µg/mL of cisplatin (Figure 3A). In contrast, defragmenta-
tion of DNA following treatment of ORL-48 with 
α-tocopherol produced a smearing (Figure 3B).
Percentage Presence of Apoptotic Cells—TUNEL 
Assay
The apoptosis ratio induced by α-tocopherol and cisplatin 
on ORL-48 cells were quantitatively assessed by flow 
cytometry. Cells present in the P2 region were classified as 
control or untreated cancer cells. Fluorescent apoptotic cells 
stained with V-FITC appeared in regions labeled P3 and P4 
(Figure 4) were quantitatively assessed and presented in 
percentage. Apoptotic cell death induced at various concen-
trations (2.5-10.0 µg/mL) of α-tocopherol and cisplatin was 
plotted as in Figure 5. A linear dose-dependent relationship 
between apoptotic activity and concentration of both test 
compounds were displayed at <2.5 µg/mL. Comparatively, 
however, the apoptotic strength of cisplatin was calculated 
1.6-fold stronger than that displayed by α-tocopherol. At 
higher concentrations, apoptotic cell death seemed incon-
sistent, which eventually reaches a plateau.
Apoptotic Cell Presence Using Annexin V-Biotin 
Apoptosis Assay
The induction of programmed cell death exerted by cispla-
tin and α-tocopherol on ORL-48 cells were determined by 
flow cytometry using Annexin V-FITC/PI double staining 
Table 1. Cytotoxic Activity of Cisplatin and α-Tocopherol on 
Cancerous Oral Mucosal Cells ORL-48 and Human Epidermal 
Keratinocytes Measured by the Concentration Required to 
Inhibit 50% of Cell Proliferation (IC
50
).
Treatment
IC
50
 (µg/mL)
Oral Mucosal 
ORL-48
Human Epidermal 
Keratinocytes
Cisplatin 1.0 ± 0.2 <0.1
α-Tocopherol 2.5 ± 0.4 4.08 ± 0.05
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approach. Untreated cell was found in the lower left quad-
rant of the cytograms, these viable cells excluded PI and 
were negative for Annexin V binding. The upper right quad-
rant represents the nonviable, necrotic cells, positive for 
Annexin V binding and showing PI uptake. The lower right 
quadrant represents the apoptotic cells, Annexin V positive 
and PI negative, demonstrating Annexin V binding and 
cytoplasmic membrane integrity (Figure 5). Treated ORL-
48 cells were stained positive for Annexin V and negative 
for propidium iodide (FITC+/PI−) with a significant 
increase of apoptotic cells from 0.2% to 19.7% (cisplatin) 
and 21.1% (α-tocopherol) (Figure 6).
Cell Cycle Analysis
At different stages of the cell cycle, cell nuclei contain dif-
ferent amounts of DNA. Flow cytometry was used to ana-
lyze cell cycle distribution of ORL-48 cells following 
exposure to cisplatin and α-tocopherol. It was determined 
that cell cycle arrest was induced at the Sub G0 phase (Table 
2) for both cisplatin and α-tocopherol showing a significant 
(P < .05) increase in cell population from 7.0% to 19.7% 
and 7.0% to 21.4%, respectively. Most of the cells were 
accumulated in the G0/G1 peak for both (Figure 7).
Discussion
Cisplatin is a widely prescribed chemotherapeutic drug 
reported efficient in treating head and neck squamous cell 
carcinoma.24 However, the limiting factor of this drug is 
that it has also been found to cause ototoxicity, gastrotoxic-
ity, myelosuppression, nephrotoxicity, and allergic reac-
tions and the effect is reported to be dose dependent.25 It 
was reported much earlier that at low concentrations, cispl-
atin induces apoptotic cell death but at higher concentra-
tion, necrosis ensues.26 Other report explained the cytotoxic 
action of cisplatin was determined through interaction with 
DNA, and cell death was exhibited by the loss of cell attach-
ment to the ground matrix resulting in floating cells, accom-
panied also by blebbing of the cell membrane.27 It is thus 
important to determine whether any cellular response to 
cisplatin is a function of the extent of drug uptake or whether 
it reflects the inherent cellular sensitivity to DNA damage. 
Studies have shown that cultured mammalian cells vary 
widely in their capacity to tolerate cisplatin-induced DNA 
damage.28,29 To enhance the antitumor effect of cisplatin, a 
combinatorial chemotherapy approach whereby cisplatin 
was used together with agents such as etoposide and bleo-
mycin are being studied.30
α-Tocopherol was reported effective in enhancing the 
tumor growth inhibition activity of cisplatin. α-Tocopherol 
is said to function by modulating the permeability of tumour 
cell membrane that increases the influx of cisplatin, which 
then causes the DNA repair machinery to be less efficient 
due to increased efficiency of adduct formation in the DNA 
molecule. This effect of α-tocopherol would then render 
cisplatin more effective as an antitumour agent.31 As an 
active isomer of vitamin E, α-tocopherol is known for its 
Figure 1. Time lapse microscopy recorded changes on ORL-48 cells on treatment with both (A) 2.5 µg/mL of cisplatin and (B) 
2.5 µg/mL of α-tocopherol (vitamin E) over a period of 72 hours. Images were captured using Juli Br-Live cell movie analyzer (40× 
magnification).
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potent antioxidant property. With free phenol hydroxyl 
group present in its functional moiety, α-tocopherol sup-
presses the toxic effect of free radicals through the interac-
tion of a variety of cellular molecules that eventually leads 
to the inhibition or alteration of cell function through lipid 
peroxidation. α-Tocopherol has also been reported to induce 
apoptosis in erythroid leukemia and in prostate and breast 
cancer cells.14
In this in vitro study, both α-tocopherol and cisplatin 
showed strong antitumor activity on cancer cells ORL-48 
with 50% of growth inhibition (IC
50
) determined at 2.5 ± 
0.4 and 1.0 ± 0.2 µg/mL, respectively (Table 1). The antip-
roliferative effect of α-tocopherol on oral cancer cells ORL-
48 was promising since very low dose was enough to inhibit 
50% of ORL-48 proliferation. This property is also shared 
by α-tocopheryl succinate (TOS), another isomer of vitamin 
E that exhibited similar activity on 2 human head and neck 
squamous cell cancer cell lines (JHU-013 and JHU-022 cell 
lines) at low IC
50
 of 8.6 µg/mL.32
As expected of a chemotherapeutic antitumor agent, the 
antiproliferative strength of cisplatin was determined 2.5-
fold stronger than α-tocopherol. However, an important 
concern over the application of cisplatin as an anticancer 
drug is that it was determined cytotoxic on normal human 
oral keratinocytes (Table 1). This adds to the concerns of 
earlier researchers on the nonselectivity of this drug on 
targeted carcinogenic cells.10 Combining the therapeutic 
effects of cisplatin with other active agents thus, is heavily 
undertaken with the aim to enhance its antitumor activity 
on cisplatin-resistant tumor and at the same time to reduce 
its side effects that would improve the clinical condition of 
patients.31 In this study, it was found that in contrast to 
cisplatin, α-tocopherol was determined nontoxic on nor-
mal human keratinocytes and exhibited promising 
Figure 2. Transmission electron micrographs showing the ORL-48 cells; untreated (A and B), treated with 2.5 µg/mL cisplatin 
(C), and treated with 2.5 µg/mL α-tocopherol (D). (4000× magnification). A, nucleolus; B, nucleus; C, nuclear membrane; D, plasma 
membrane; E, vacuole.
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antitumor activity on squamous oral cancer cells ORL-48. 
It has been reported that the activity of α-tocopherol could 
be associated with the presence of chromanol ring system 
in its structure. Chromanols are a family of phenolic com-
pounds that in addition to a chromanol ring system also 
has a 16-carbon aliphatic side-chain. The presence of 
chromanol is said to target mitochondria, which exhibit 
the selective anti-proliferative effects.33 α-Tocopherol is 
also an intracellular antioxidant which has been reported 
to inhibit lipid peroxidation of polyunsaturated fatty acid 
located in lipid membrane.34
With regard to the mechanism of cell death, α-tocopherol 
was found to induce morphological effect on ORL-48. 
Through time lapse monitoring, alteration of cell morphol-
ogy that included distinct shrinkage of cell sizes was 
observed very early at 3 hours of treatment, and gradually 
became prominent over the 72-hour treatment period 
before it finally showed the appearance of apoptotic bodies 
at 24 hours (Figure 1B). Most of the characteristics reported 
as signs of apoptosis in earlier references were observed. 
Gradual reduction in cell population with time was also 
noted. Interestingly, however, these observations were not 
exhibited following cisplatin-treatment. Instead, a slow but 
gradual increase in cell population was noticed (Figure 
1A). The contrasting morphological responses of ORL-48 
induced by tocopherol and cisplatin may suggest the differ-
ent adaptation of ORL-48 when cultured under in vitro 
condition.35 Morphologic heterogeneity is a typical feature 
of malignant cell lines and has usually been attributed to 
genetic instability and clonal evolution. It was reported that 
this behaviorally different subpopulation is probably due to 
the presence of cells with a range of differing proliferative 
capabilities, suggesting the presence of cells having differ-
ing clongenic potentials.35 This situation may suggest the 
suppression of meroclones and paraclones in ORL-48 by 
cisplatin, leaving behind the holoclones. Holoclone is the 
most proliferative morphologic heterogeneity, which then 
regrows to harbor tumorigenic cells as indicated by the 
gradual increased in cell population observed following its 
treatment (Figure 1A); hence suggesting its resistance to 
cisplatin therapy.
The apoptotic effect of cisplatin on ORL-48 was vali-
dated by the ladder pattern of defragmented DNA bands 
produced by electrophoresis. Such pattern was observed 
for cisplatin with bands of best intensity obtained at 7.5 
µg/mL of cisplatin (Figure 3A). Despite the signs of 
apoptosis exhibited on ORL-48 by α-tocopherol (Figure 
1B), the ladder band pattern was not observed, instead 
replaced by a smearing (Figure 3B). The absence of 
DNA defragmentation activity was suggested not an 
absolute indication of negative apoptosis. It has been 
reported earlier that cells can also undergo apoptosis 
without showing DNA fragmentation due to lack of cas-
pase-3, which is essential for fragmentation of cell chro-
mosomal DNA during tumor necrosis factor–induced 
apoptosis.36 Caspase activates the endonuclease cas-
pase-activated DNase (CAD) responsible for fragmenta-
tion of the DNA at the linker region between 
nucleosomes.37,38 Results obtained through immunohis-
tochemical and flow cytometric procedures strongly 
suggested the apoptotic mode of activity by both test 
agents on ORL-48 (Figure 3). The apoptotic activity of 
both α-tocopherol and cisplatin was also found to follow 
a dose-dependent relationship in TUNEL assay at con-
centration of 2.5 µg/mL and lower (Figure 4). The apop-
totic strength of cisplatin at this concentration was 
however, significantly 1.6-fold stronger than 
α-tocopherol (P < .05). The apoptotic activity of both 
compounds was not stable at higher concentrations 
(Figure 4). Apoptotic cell death by both test agents was 
further validated by Annexin V-FITC (Figure 5) and 
TEM micrographs. Figure 2 showed the presence of cel-
lular shrinking, chromatin condensation, and blebbing 
of plasma membrane.
Cell cycle arrest is a stopping point in the cell cycle 
and this was induced at the sub-G0 phase for both cis-
platin and α-tocopherol (Table 2) showing a significant 
Figure 3. Expression of DNA fragments from ORL-48 cells 
after treatment with various concentrations of (A) cisplatin and 
(B) α-tocopherol.
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increase in cell population from 7.0% to 19.7% and 
7.0% to 21.4%, respectively (P < .05). It is a resting 
phase, a period in the cell cycle in which cells exist in a 
quiescent state where the cell is neither dividing nor pre-
paring to divide, or a distinct quiescent stage that occurs 
outside of the cell cycle. Most of the cells were accumu-
lated in the G0/G1 peak for both. Any stimulus that initi-
ates cell proliferation needs to promote G0/G1 transition 
and the entry of cells into the first, that is, G1, phase of 
the cycle. Once the cells enter the S phase, the DNA is 
replicated and the cell progresses through G2 and 
mitosis.39
This is the first part of the study to look into the in vitro 
responses of α-tocopherol. In order to further study the use-
fulness of α-tocopherol, a follow-up study on this may 
include its oral administration in nude mice or in mice 
where oral cancer is already induced.
Figure 4. Percentage presence of apoptotic cells on treatment at various concentrations of α-tocopherol comparative to cisplatin: 
(i) Control; (ii), (iv), (vi), and (viii)—2.5, 5.0, 7.5, and 10.0 µg/mL of α-tocopherol, respectively and (iii), (v), (vii), and (ix)—2.5, 5.0, 7.5, 
and 10.0 µg/mL of cisplatin, respectively.
Figure 5. Graph showing the effect of both cisplatin and α-
tocopherol at various concentrations on the apoptotic activity 
of ORL-48. The percentage presence of apoptotic cells was 
generated from flow cytometry observations in Figure 4.
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Conclusion
Concluding from the study, α-tocopherol was found to 
exhibit strong antitumor activity on oral cancer cell ORL-
48 without incurring toxicity on human epidermal kerati-
nocytes. Despite exhibiting lower antiproliferative potency 
comparative to cisplatin, the induction of cell death by 
α-tocopherol occurred much earlier. The mode of cell death 
by α-tocopherol suggested by electrophoresis and flow 
cytometry techniques was via apoptosis. The mechanism 
of action may involve damaging the plasma membrane, 
which then leads to shrinking of the cells without involving 
the activation of caspase molecules as in many cases of 
antitumor activity. It is thus concluded that α-tocopherol 
showed potential as a good antitumour agent for used in the 
treatment of oral cancer and hence, merits further investi-
gations into its specific molecular targets in order to be put 
it into use for the treatment of cancers.
Table 2. Effect of Cisplatin and α-Tocopherol on Cell Cycle Distribution of ORL-48 Cells.
Treatment Sub G0 (%) G0/G1 (%) S (%) G2/M (%)
Control 7.0 28.4 12.8 10.4
Cisplatin 19.7 24.1 11.8 8.7
α-Tocopherol 21.4 27.7 15.5 5.1
Figure 6. Dot plots of Annexin V-FITC/PI–stained ORL-48 cells exposed to (A) control (media only), (B) 2.5 µg/mL cisplatin, and (C) 
2.5 µg/mL α-tocopherol. The 4 quadrants represent necrotic cells (Q1: Annexin V negative; PI positive), late apoptotic or necrotic 
cells (Q2: Annexin V positive; PI positive), viable cells (Q3: Annexin V negative; PI negative), and early apoptotic cells (Q4: Annexin V 
positive; PI negative). Numbers indicate the percentage of cells in each quadrant and a minimum of 10 000 events were read.
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